CA3219586A1 - Novel protein and nucleic acid sequences for covid-19 vaccines - Google Patents

Novel protein and nucleic acid sequences for covid-19 vaccines Download PDF

Info

Publication number
CA3219586A1
CA3219586A1 CA3219586A CA3219586A CA3219586A1 CA 3219586 A1 CA3219586 A1 CA 3219586A1 CA 3219586 A CA3219586 A CA 3219586A CA 3219586 A CA3219586 A CA 3219586A CA 3219586 A1 CA3219586 A1 CA 3219586A1
Authority
CA
Canada
Prior art keywords
seq
aminoacid
cov
sars
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219586A
Other languages
English (en)
French (fr)
Inventor
Marcello Allegretti
Annamaria Cimini
Andrea Rosario Beccari
Carmine TALARICO
Elisabetta Maria Ester MAURI
Franca Cattani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3219586A1 publication Critical patent/CA3219586A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3219586A 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines Pending CA3219586A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173941.2A EP4088738A1 (en) 2021-05-14 2021-05-14 Novel protein and nucleic acid sequences for covid-19 vaccines
EP21173941.2 2021-05-14
PCT/EP2022/063214 WO2022238585A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Publications (1)

Publication Number Publication Date
CA3219586A1 true CA3219586A1 (en) 2022-11-17

Family

ID=75936784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219586A Pending CA3219586A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Country Status (10)

Country Link
US (1) US20250282831A1 (enExample)
EP (2) EP4088738A1 (enExample)
JP (1) JP2024517345A (enExample)
CN (1) CN117915945A (enExample)
AU (1) AU2022272659A1 (enExample)
BR (1) BR112023023794A2 (enExample)
CA (1) CA3219586A1 (enExample)
IL (1) IL308407A (enExample)
WO (1) WO2022238585A1 (enExample)
ZA (1) ZA202311432B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗

Also Published As

Publication number Publication date
EP4088738A1 (en) 2022-11-16
CN117915945A (zh) 2024-04-19
AU2022272659A1 (en) 2023-11-23
JP2024517345A (ja) 2024-04-19
WO2022238585A1 (en) 2022-11-17
AU2022272659A9 (en) 2023-11-30
ZA202311432B (en) 2025-04-30
US20250282831A1 (en) 2025-09-11
IL308407A (en) 2024-01-01
BR112023023794A2 (pt) 2024-03-12
EP4337250A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
CN106573960B (zh) 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
CN114106164B (zh) 抗新型冠状病毒s蛋白的单克隆抗体及其应用
EP2970397A2 (en) Polypeptides for treating and/or limiting influenza infection
JP5042237B2 (ja) 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
Chung et al. Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency
JP2026010683A (ja) 呼吸器合胞体ウイルスのｍＲＮＡワクチン及びその調製方法と使用
US20250282831A1 (en) Novel protein and nucleic acid sequences for covid-19 vaccines
EP4707293A1 (en) Mutant of rsv f protein
US20240180889A1 (en) Combination therapy for covid-19 vaccination
Shah et al. Overexpression and characterization of the 100K protein of Fowl adenovirus-4 as an antiviral target
JPWO2004091476A1 (ja) 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物
RU2633068C2 (ru) Способ измерения антитела против wt1
CN112262153B (zh) 高效的肝炎病毒的抗体诱导方法、抗体以及检测系统
US20170198014A1 (en) Polypeptides and their use for treating influenza
KR101123130B1 (ko) Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CN116813767A (zh) 一种fgf21蛋白多克隆抗体制备方法
JP2013507102A (ja) シャペロニン１０変異体
US6558675B1 (en) Mutant human hepatitis B viral strain and uses thereof
JP4368578B2 (ja) 遺伝子免疫による抗体作製法
CN121494944B (zh) 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用
RU2856219C1 (ru) Рекомбинантная плазмидная ДНК pET-22b-sars"XBB.1.5", обеспечивающая получение рекомбинантного белка коронавируса S-SARS"XBB.1.5", обладающего способностью определять уровень вирус-специфических IgG к антигенному варианту вируса "кракен" - SARS"XBB.1.5"
US20030003111A1 (en) Mutant human hepatitis B viral strain and uses thereof
JPWO2002008416A1 (ja) 遺伝子免疫による抗体作製法
RU2562880C2 (ru) Синтетический пептид для получения моноспецифичных антител против изоформы 2 эукариотического фактора элонгации трансляции 1а
HK40106052A (en) Mutants of rsv f protein

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260305

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260305